Key Points
-
Streptococcus pyogenes, also called group A Streptococcus (GAS), is a Gram-positive bacterial pathogen that naturally infects only humans and is the aetiological agent of several potentially fatal syndromes, including 'flesh-eating disease' (necrotizing fasciitis).
-
The worldwide resurgence of severe invasive GAS infections over the past 30 years is correlated with the global dissemination of the GAS serotype M1T1 clone.
-
Recent work demonstrates that the capacity of GAS serotype M1T1 to cause invasive disease is increased by selection for mutations within the covRS two-component regulator operon. This genetic alteration dramatically changes the transcriptome, resulting in the downregulation of a broad-spectrum cysteine protease, streptococcal pyrogenic exotoxin B (SpeB), and the upregulation of several virulence factors, including the nuclease extracellular streptodornase D (Sda1).
-
Elevated Sda1 nuclease activity enhances the resistance of GAS serotype M1T1 to neutrophil-mediated killing, through the degradation of DNA-based neutrophil extracellular traps, and the absence of SpeB protease activity permits the accumulation of plasmin activity on the GAS cell surface, triggering tissue destruction and systemic spread.
-
GAS uses a repertoire of virulence factors to thwart the host innate immune response, and several of these factors are critical for invasive disease. The switch from non-invasive to hyperinvasive GAS is triggered by particular genetic events, and our increased understanding of this switch has led to a model for the initiation of invasive GAS disease in humans.
-
An understanding of the mechanism by which GAS causes serious invasive infections may augment the development of new-generation therapeutics and provide better health outcomes in the fight against this globally important human pathogen.
Abstract
Streptococcus pyogenes is also known as group A Streptococcus (GAS) and is an important human pathogen that causes considerable morbidity and mortality worldwide. The GAS serotype M1T1 clone is the most frequently isolated serotype from life-threatening invasive (at a sterile site) infections, such as streptococcal toxic shock-like syndrome and necrotizing fasciitis. Here, we describe the virulence factors and newly discovered molecular events that mediate the in vivo changes from non-invasive GAS serotype M1T1 to the invasive phenotype, and review the invasive-disease trigger for non-M1 GAS. Understanding the molecular basis and mechanism of initiation for streptococcal invasive disease may expedite the discovery of novel therapeutic targets for the treatment and control of severe invasive GAS diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 5, 685â694 (2005).
Cunningham, M. W. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13, 470â511 (2000).
Young, M. H., Aronoff, D. M. & Engleberg, N. C. Necrotizing fasciitis: pathogenesis and treatment. Expert Rev. Anti. Infect. Ther. 3, 279â294 (2005).
Cole, J. N., Henningham, A., Gillen, C. M., Ramachandran, V. & Walker, M. J. Human pathogenic streptococcal proteomics and vaccine development. Proteomics Clin. Appl. 2, 387â410 (2008). An overview of streptococcal proteomics and the selection of antigens as novel vaccine candidates.
Beall, B., Facklam, R. & Thompson, T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J. Clin. Microbiol. 34, 953â958 (1996).
Shulman, S. T. et al. Group A streptococcal pharyngitis serotype surveillance in North America, 2000â2002 Clin. Infect. Dis. 39, 325â332 (2004).
Steer, A. C., Law, I., Matatolu, L., Beall, B. W. & Carapetis, J. R. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect. Dis. 9, 611â616 (2009).
Aziz, R. K. & Kotb, M. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg. Infect. Dis. 14, 1511â1517 (2008).
Tart, A. H., Walker, M. J. & Musser, J. M. New understanding of the group A Streptococcus pathogenesis cycle. Trends Microbiol. 15, 318â325 (2007).
Sumby, P. et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group A Streptococcus involved multiple horizontal gene transfer events. J. Infect. Dis. 192, 771â782 (2005).
Sumby, P., Whitney, A. R., Graviss, E. A., DeLeo, F. R. & Musser, J. M. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog. 2, e5 (2006). The original report demonstrating that phenotypic changes in GAS serotype M1T1 are caused solely by mutations within the covRS two-component regulator operon.
Walker, M. J. et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nature Med. 13, 981â985 (2007). The first demonstration that the nuclease Sda1 provides selection pressure for the emergence of covRS mutants of GAS serotype M1T1 in vivo.
Pence, M. A. et al. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. J. Innate Immun. 2, 587â595 (2010).
Engleberg, N. C., Heath, A., Miller, A., Rivera, C. & DiRita, V. J. Spontaneous mutations in the csrRS two component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J. Infect. Dis. 183, 1043â1054 (2001).
Zinkernagel, A. S. et al. The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe 4, 170â178 (2008).
Timmer, A. M. et al. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J. Biol. Chem. 284, 862â871 (2009).
Sumby, P. et al. Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc. Natl Acad. Sci. USA 102, 1679â1684 (2005).
Buchanan, J. T. et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol. 16, 396â400 (2006). The demonstration that the nuclease Sda1 enhances GAS serotype M1T1 resistance to neutrophil killing through the destruction of NETs.
Kansal, R. G., McGeer, A., Low, D. E., Norrby-Teglund, A. & Kotb, M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect. Immun. 68, 6362â6369 (2000). An epidemiological study documenting that clinical GAS isolates from severe invasive infections exhibit less SpeB protease activity.
Aziz, R. K. et al. Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Mol. Microbiol. 51, 123â134 (2004). Proteomic analyses showing that covRS mutations results in the downregulation of SpeB protease activity and the upregulation of multiple GAS serotype M1T1 virulence factors.
Cole, J. N. et al. Trigger for group A streptococcal M1T1 invasive disease. FASEB J. 20, 1745â1747 (2006). The first report to document that a loss of SpeB activity through covRS mutation permits the accumulation of cell surface protease activity and subsequent GAS serotype M1T1 dissemination in vivo.
Lamagni, T. L. et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J. Clin. Microbiol. 46, 2359â2367 (2008).
O'Grady, K. A. et al. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med. J. Aust. 186, 565â569 (2007).
O'Loughlin, R. E. et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000â2004. Clin. Infect. Dis. 45, 853â862 (2007).
Sharkawy, A. et al. Severe group A streptococcal soft-tissue infections in Ontario: 1992â1996. Clin. Infect. Dis. 34, 454â460 (2002).
Courtney, H. S., Hasty, D. L. & Dale, J. B. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann. Med. 34, 77â87 (2002).
Nobbs, A. H., Lamont, R. J. & Jenkinson, H. F. Streptococcus adherence and colonization. Microbiol. Mol. Biol. Rev. 73, 407â450 (2009).
Abbot, E. L. et al. Pili mediate specific adhesion of Streptococcus pyogenes to human tonsil and skin. Cell. Microbiol. 9, 1822â1833 (2007).
Kreikemeyer, B., Klenk, M. & Podbielski, A. The intracellular status of Streptococcus pyogenes: role of extracellular matrix-binding proteins and their regulation. Int. J. Med. Microbiol. 294, 177â188 (2004).
Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532â1535 (2004).
Okada, N., Liszewski, M. K., Atkinson, J. P. & Caparon, M. Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A Streptococcus. Proc. Natl Acad. Sci. USA 92, 2489â2493 (1995).
Horstmann, R. D., Sievertsen, H. J., Leippe, M. & Fischetti, V. A. Role of fibrinogen in complement inhibition by streptococcal M protein. Infect. Immun. 60, 5036â5041 (1992).
Carlsson, F., Berggard, K., Stalhammar-Carlemalm, M. & Lindahl, G. Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein. J. Exp. Med. 198, 1057â1068 (2003).
Staali, L., Bauer, S., Morgelin, M., Bjorck, L. & Tapper, H. Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. Cell. Microbiol. 8, 690â703 (2006).
Lauth, X. et al. M1 protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. J. Innate Immun. 1, 202â214 (2009). A report describing the finding that M1 protein enhances bacterial survival of neutrophil-mediated killing through inhibition of human antimicrobial peptides.
Ashbaugh, C. D., Warren, H. B., Carey, V. J. & Wessels, M. R. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J. Clin. Invest. 102, 550â560 (1998).
Dale, J. B. & Chiang, E. C. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J. Infect. Dis. 171, 1038â1041 (1995).
Bober, M., Enochsson, C., Collin, M. & Morgelin, M. Collagen VI is a subepithelial adhesive target for human respiratory tract pathogens. J. Innate Immun. 2, 160â166 (2010).
Crater, D. L. & van de Rijn, I. Hyaluronic acid synthesis operon (has) expression in group A streptococci. J. Biol. Chem. 270, 18452â18458 (1995).
Dale, J., Washburn, R., Marques, M. & Wessels, M. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect. Immun. 64, 1495â1501 (1996).
Wessels, M. R., Moses, A. E., Goldberg, J. B. & DiCesare, T. J. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc. Natl Acad. Sci. USA 88, 8317â8321 (1991).
Cole, J. N. et al. M protein and hyaluronic acid are essential for in vivo selection of covRS mutations characteristic of invasive M1T1 group A Streptococcus. mBio 1, e00191â00110 (2010). The first demonstration that M1 protein and the hyaluronic acid capsule are essential for the invasive phenotype of GAS serotype M1T1 in vivo.
Moses, A. et al. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect. Immun. 65, 64â71 (1997).
Bhakdi, S., Tranum-Jensen, J. & Sziegoleit, A. Mechanism of membrane damage by streptolysin-O. Infect. Immun. 47, 52â60 (1985).
Madden, J. C., Ruiz, N. & Caparon, M. Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in Gram-positive bacteria. Cell 104, 143â152 (2001).
Bricker, A. L., Cywes, C., Ashbaugh, C. D. & Wessels, M. R. NAD+-glycohydrolase acts as an intracellular toxin to enhance the extracellular survival of group A streptococci. Mol. Microbiol. 44, 257â269 (2002).
Hakansson, A., Bentley, C. C., Shakhnovic, E. A. & Wessels, M. R. Cytolysin-dependent evasion of lysosomal killing. Proc. Natl Acad. Sci. USA 102, 5192â5197 (2005).
Nakagawa, I. et al. Autophagy defends cells against invading group A Streptococcus. Science 306, 1037â1040 (2004).
Brosnahan, A. J., Mantz, M. J., Squier, C. A., Peterson, M. L. & Schlievert, P. M. Cytolysins augment superantigen penetration of stratified mucosa. J. Immunol. 182, 2364â2373 (2009).
Limbago, B., Penumalli, V., Weinrick, B. & Scott, J. R. Role of streptolysin O in a mouse model of invasive group A streptococcal disease. Infect. Immun. 68, 6384â6390 (2000).
Ato, M., Ikebe, T., Kawabata, H., Takemori, T. & Watanabe, H. Incompetence of neutrophils to invasive group A Streptococcus is attributed to induction of plural virulence factors by dysfunction of a regulator. PLoS ONE 3, e3455 (2008).
Edwards, R. J. et al. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis. 192, 783â790 (2005).
Kurupati, P. et al. Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract. Mol. Microbiol. 76, 1387â1397 (2010).
Turner, C. E., Kurupati, P., Wiles, S., Edwards, R. J. & Sriskandan, S. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine 27, 4923â4929 (2009).
Turner, C. E., Kurupati, P., Jones, M. D., Edwards, R. J. & Sriskandan, S. Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection. J. Infect. Dis. 200, 555â563 (2009).
Fernie-King, B. A. et al. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 103, 390â398 (2001).
Fernie-King, B. A., Seilly, D. J., Davies, A. & Lachmann, P. J. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect. Immun. 70, 4908â4916 (2002).
Fernie-King, B. A., Seilly, D. J. & Lachmann, P. J. The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. Immunology 111, 444â452 (2004).
Frick, I. M., Akesson, P., Rasmussen, M., Schmidtchen, A. & Bjorck, L. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J. Biol. Chem. 278, 16561â16566 (2003).
Lei, B. et al. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nature Med. 7, 1298â1305 (2001).
von Pawel-Rammingen, U., Johansson, B. P. & Bjorck, L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J. 21, 1607â1615 (2002).
Trevino, J. et al. CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect. Immun. 77, 3141â3149 (2009).
Zhu, H., Liu, M., Sumby, P. & Lei, B. The secreted esterase of group A Streptococcus is important for invasive skin infection and dissemination in mice. Infect. Immun. 77, 5225â5232 (2009).
Boyle, M. D. & Lottenberg, R. Plasminogen activation by invasive human pathogens. Thromb. Haemost. 77, 1â10 (1997).
Coleman, J. L. & Benach, J. L. Use of the plasminogen activation system by microorganisms. J. Lab. Clin. Med. 134, 567â576 (1999).
Werb, Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439â442 (1997).
Svensson, M. D., Sjobring, U., Luo, F. & Bessen, D. E. Roles of the plasminogen activator streptokinase and the plasminogen-associated M protein in an experimental model for streptococcal impetigo. Microbiology 148, 3933â3945 (2002).
Khil, J. et al. Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms. J. Infect. Dis. 188, 497â505 (2003).
Li, Z., Ploplis, V. A., French, E. L. & Boyle, M. D. Interaction between group A streptococci and the plasmin(ogen) system promotes virulence in a mouse skin infection model. J. Infect. Dis. 179, 907â914 (1999).
Lahteenmaki, K., Kuusela, P. & Korhonen, T. K. Bacterial plasminogen activators and receptors. FEMS Microbiol. Rev. 25, 531â552 (2001).
Sun, H. et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 305, 1283â1286 (2004). A report showing that human plasminogen is activated to plasmin on the GAS cell surface, allowing the destruction of host tissue barriers and triggering systemic spread.
Pancholi, V., Fontan, P. & Jin, H. Plasminogen-mediated group A streptococcal adherence to and pericellular invasion of human pharyngeal cells. Microb. Pathog. 35, 293â303 (2003).
Derbise, A., Song, Y. P., Parikh, S., Fischetti, V. A. & Pancholi, V. Role of the C-terminal lysine residues of streptococcal surface enolase in Glu- and Lys-plasminogen-binding activities of group A streptococci. Infect. Immun. 72, 94â105 (2004).
Berge, A. & Sjobring, U. PAM, a novel plasminogen-binding protein from Streptococcus pyogenes. J. Biol. Chem. 268, 25417â25424 (1993).
Sanderson-Smith, M. L. et al. M protein-mediated plasminogen binding is essential for the virulence of an invasive Streptococcus pyogenes isolate. FASEB J. 22, 2715â2722 (2008).
Pancholi, V. & Fischetti, V. A. α-Enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J. Biol. Chem. 273, 14503â14515 (1998).
Cork, A. J. et al. Defining the structural basis of human plasminogen binding by streptococcal surface enolase. J. Biol. Chem. 284, 17129â17137 (2009).
Pancholi, V. & Fischetti, V. A major surface protein on group A streptococci is a glyceraldehyde-3-phosphate-dehydrogenase with multiple binding activity. J. Exp. Med. 176, 415â426 (1992).
Lottenberg, R. et al. Cloning, sequence analysis, and expression in Escherichia coli of a streptococcal plasmin receptor. J. Bacteriol. 174, 5204â5210 (1992).
McKay, F. C. et al. Plasminogen binding by group A streptococcal isolates from a region of hyperendemicity for streptococcal skin infection and a high incidence of invasive infection. Infect. Immun. 72, 364â370 (2004).
Wang, H., Lottenberg, R. & Boyle, M. D. A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci. J. Infect. Dis. 171, 85â92 (1995).
Wang, H., Lottenberg, R. & Boyle, M. D. Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microb. Pathog. 18, 153â166 (1995).
Lottenberg, R., Minning-Wenz, D. & Boyle, M. D. Capturing host plasmin(ogen): a common mechanism for invasive pathogens? Trends Microbiol. 2, 20â24 (1994).
Lijnen, H. R. et al. Mechanisms of plasminogen activation. J. Intern. Med. 236, 415â424 (1994).
Herwald, H. et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell 116, 367â379 (2004).
Walker, M. J., McArthur, J. D., McKay, F. & Ranson, M. Is plasminogen deployed as a Streptococcus pyogenes virulence factor? Trends Microbiol. 13, 308â313 (2005).
Hytonen, J., Haataja, S., Gerlach, D., Podbielski, A. & Finne, J. The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin-binding and cysteine protease activity. Mol. Microbiol. 39, 512â519 (2001).
Chaussee, M. S., Liu, J., Stevens, D. L. & Ferretti, J. J. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J. Infect. Dis. 173, 901â908 (1996).
Chaussee, M. S., Phillips, E. R. & Ferretti, J. J. Temporal production of streptococcal erythrogenic toxin B (streptococcal cysteine proteinase) in response to nutrient depletion. Infect. Immun. 65, 1956â1959 (1997).
Loughman, J. A. & Caparon, M. Regulation of SpeB in Streptococcus pyogenes by pH and NaCl: a model for in vivo gene expression. J. Bacteriol. 188, 399â408 (2006).
Musser, J., Stockbauer, K., Kapur, V. & Rudgers, G. Substitution of cysteine 192 in a highly conserved Streptococcus pyogenes extracellular cysteine protease (interleukin 1β convertase) alters proteolytic activity and ablates zymogen processing. Infect. Immun. 64, 1913â1917 (1996).
Shelburne, S. A. 3rd et al. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect. Immun. 73, 4723â4731 (2005).
Eriksson, A. & Norgren, M. Cleavage of antigen-bound immunoglobulin G by SpeB contributes to streptococcal persistence in opsonizing blood. Infect. Immun. 71, 211â217 (2003).
Nyberg, P., Rasmussen, M. & Bjorck, L. α2-Macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J. Biol. Chem. 279, 52820â52823 (2004).
Ringdahl, U. et al. A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. Mol. Microbiol. 37, 1318â1326 (2000).
Kansal, R. G., Nizet, V., Jeng, A., Chuang, W. J. & Kotb, M. Selective modulation of superantigen-induced responses by streptococcal cysteine protease. J. Infect. Dis. 187, 398â407 (2003).
Raeder, R., Woischnik, M., Podbielski, A. & Boyle, M. D. A secreted streptococcal cysteine protease can cleave a surface-expressed M1 protein and alter the immunoglobulin binding properties. Res. Microbiol. 149, 539â548 (1998).
Chatellier, S. et al. Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect. Immun. 68, 3523â3534 (2000).
Hollands, A. et al. A naturally occurring mutation in ropB suppresses SpeB expression and reduces M1T1 group A streptococcal systemic virulence. PLoS ONE 3, e4102 (2008).
Ikebe, T. et al. Highly frequent mutations in negative regulators of multiple virulence genes in group A streptococcal toxic shock syndrome isolates. PLoS Pathog. 6, e1000832 (2010).
Carroll, R. K. et al. Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. J. Clin. Invest. 121, 1956â1968 (2011).
Aziz, R. K. et al. Mosaic prophages with horizontally acquired genes account for the emergence and diversification of the globally disseminated M1T1 clone of Streptococcus pyogenes. J. Bacteriol. 187, 3311â3318 (2005).
Dalton, T., Collins, J., Barnett, T. & Scott, J. RscA, a member of the MDR1 family of transporters, is repressed by CovR and required for growth of Streptococcus pyogenes under heat stress. J. Bacteriol. 188, 77â85 (2006).
Shea, P. R. et al. Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proc. Natl Acad. Sci. USA 108, 5039â5044 (2011).
Dalton, T. L. & Scott, J. R. CovS inactivates CovR and is required for growth under conditions of general stress in Streptococcus pyogenes. J. Bacteriol. 186, 3928â3937 (2004).
Froehlich, B., Bates, C. & Scott, J. Streptococcus pyogenes CovR/S mediates growth in iron starvation and in the presence of the human cationic antimicrobial peptide LL-37. J. Bacteriol. 191, 673â677 (2009).
Sawai, J. et al. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes. Antimicrob. Agents Chemother. 51, 461â467 (2007).
Gryllos, I., Levin, J. C. & Wessels, M. R. The CsrR/CsrS two-component system of group A Streptococcus responds to environmental Mg2+. Proc. Natl Acad. Sci. USA 100, 4227â4232 (2003).
Levin, J. & Wessels, M. Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Mol. Microbiol. 30, 209â219 (1998).
Heath, A., DiRita, V. J., Barg, N. L. & Engleberg, N. C. A two-component regulatory system, CsrR-CsrS, represses expression of three Streptococcus pyogenes virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect. Immun. 67, 5298â5305 (1999).
Graham, M. R. et al. Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am. J. Pathol. 166, 455â465 (2005).
Churchward, G. The two faces of Janus: virulence gene regulation by CovR/S in group A streptococci. Mol. Microbiol. 64, 34â41 (2007).
Kansal, R. G. et al. Dissection of the molecular basis for hypervirulence of an in vivo-selected phenotype of the widely disseminated M1T1 strain of group A Streptococcus bacteria. J. Infect. Dis. 201, 855â865 (2010).
Aziz, R. K. et al. Microevolution of group A streptococci in vivo: capturing regulatory networks engaged in sociomicrobiology, niche adaptation, and hypervirulence. PLoS ONE 5, e9798 (2010).
Svensson, M. D. et al. Role for a secreted cysteine proteinase in the establishment of host tissue tropism by group A streptococci. Mol. Microbiol. 38, 242â253 (2000).
Hassell, M., Fagan, P., Carson, P. & Currie, B. J. Streptococcal necrotising fasciitis from diverse strains of Streptococcus pyogenes in tropical northern Australia: case series and comparison with the literature. BMC Infect. Dis. 4, 60 (2004).
Husmann, L. K., Yung, D. L., Hollingshead, S. K. & Scott, J. R. Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. Infect. Immun. 65, 1422â1430 (1997).
Ravins, M. et al. Characterization of a mouse passaged, highly encapsulated variant of group A Streptococcus in in vitro and in vivo studies. J. Infect. Dis. 182, 1702â1711 (2000).
Courtney, H. S., Ofek, I. & Hasty, D. L. M protein mediated adhesion of M type 24 Streptococcus pyogenes stimulates release of interleukin-6 by HEp-2 tissue culture cells. FEMS Microbiol. Lett. 151, 65â70 (1997).
Miyoshi-Akiyama, T. et al. Use of DNA arrays to identify a mutation in the negative regulator, csrR, responsible for the high virulence of a naturally occurring type M3 group A Streptococcus clinical isolate. J. Infect. Dis. 193, 1677â1684 (2006).
Nakagawa, I. et al. Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res. 13, 1042â1055 (2003).
Maamary, P. G. et al. Parameters governing invasive disease propensity of non-M1 serotype group A streptococci. J. Innate Immun. 2, 596â606 (2010). The first report of non-M1 GAS undergoing covRS mutations in vivo , but at a reduced frequency compared with GAS serotype M1T1.
Sugareva, V. et al. Serotype- and strain-dependent contribution of the sensor kinase CovS of the CovRS two-component system to Streptococcus pyogenes pathogenesis. BMC Microbiol. 10, 34 (2010).
Hollands, A. et al. Genetic switch to hypervirulence reduces colonization phenotypes of the globally disseminated group A Streptococcus M1T1 Clone. J. Infect. Dis. 202, 11â19 (2010). A study showing that covRS mutants of GAS serotype M1T1 have a colonization defect compared with wild-type bacteria.
Lembke, C. et al. Characterization of biofilm formation by clinically relevant serotypes of group A streptococci. Appl. Environ. Microbiol. 72, 2864â2875 (2006).
Marcon, M. J. et al. Occurrence of mucoid M-18 Streptococcus pyogenes in a central Ohio pediatric population. J. Clin. Microbiol. 26, 1539â1542 (1988).
Stollerman, G. H. & Dale, J. B. The importance of the group A Streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin. Infect. Dis. 46, 1038â1045 (2008).
Hoe, N. P. et al. Distribution of streptococcal inhibitor of complement variants in pharyngitis and invasive isolates in an epidemic of serotype M1 group A Streptococcus infection. J. Infect. Dis. 183, 633â639 (2001).
Hasegawa, T. et al. Detection of invasive protein profile of Streptococcus pyogenes M1 isolates from pharyngitis patients. APMIS 118, 167â178 (2010).
Garcia, A. F. et al. An insert in the covS gene distinguishes a pharyngeal and a blood isolate of Streptococcus pyogenes found in the same individual. Microbiology 156, 3085â3095 (2010). The first report to document the covRS mutations of GAS serotype M81.0 in humans.
Ferretti, J. J. et al. Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc. Natl Acad. Sci. USA 98, 4658â4663 (2001).
Bryant, A. E., Bayer, C. R., Huntington, J. D. & Stevens, D. L. Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes. J. Infect. Dis. 193, 1685â1692 (2006).
McNeil, S. A. et al. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114â1122 (2005).
Choby, B. A. Diagnosis and treatment of streptococcal pharyngitis. Am. Fam. Physician 79, 383â390 (2009).
Danchin, M. H. et al. Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics 120, 950â957 (2007).
Danchin, M. H. et al. The burden of group A streptococcal pharyngitis in Melbourne families. Indian J. Med. Res. 119 (Suppl.), 144â147 (2004).
Steer, A. C. et al. Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr. Infect. Dis. J. 28, 477â482 (2009).
Nandi, S., Kumar, R., Ray, P., Vohra, H. & Ganguly, N. K. Group A streptococcal sore throat in a periurban population of northern India: a one-year prospective study. Bull. World Health Organ. 79, 528â533 (2001).
Bernard, P. Management of common bacterial infections of the skin. Curr. Opin. Infect. Dis. 21, 122â128 (2008).
Koning, S. et al. Impetigo: incidence and treatment in Dutch general practice in 1987 and 2001âresults from two national surveys. Br. J. Dermatol. 154, 239â243 (2006).
Steer, A. C. et al. High burden of impetigo and scabies in a tropical country. PLoS Negl. Trop. Dis. 3, e467 (2009).
Wong, L. C. et al. Outcome of an interventional program for scabies in an Indigenous community. Med. J. Aust. 175, 367â370 (2001).
Steer, A. C. & Carapetis, J. R. Prevention and treatment of rheumatic heart disease in the developing world. Nature Rev. Cardiol. 6, 689â698 (2009).
Carapetis, J. R., Currie, B. J. & Mathews, J. D. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population? Epidemiol. Infect. 124, 239â244 (2000).
Grover, A. et al. Epidemiology of rheumatic fever and rheumatic heart disease in a rural community in northern India. Bull. World Health Organ. 71, 59â66 (1993).
Lennon, D., Stewart, J., Farrell, E., Palmer, A. & Mason, H. School-based prevention of acute rheumatic fever: a group randomized trial in New Zealand. Pediatr. Infect. Dis. J. 28, 787â794 (2009).
Seckeler, M. D., Barton, L. L. & Brownstein, R. The persistent challenge of rheumatic fever in the Northern Mariana Islands. Int. J. Infect. Dis. 14, e226âe229.
Ahn, S. Y. & Ingulli, E. Acute poststreptococcal glomerulonephritis: an update. Curr. Opin. Pediatr. 20, 157â162 (2008).
WHO. The current evidence for the burden of group A streptococcal diseases. WHO [online], (2005).
Becquet, O. et al. Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study. Pediatr. Nephrol. 25, 275â280 (2010).
Lappin, E. & Ferguson, A. J. Gram-positive toxic shock syndromes. Lancet Infect. Dis. 9, 281â290 (2009).
Lamagni, T. L. et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003â2004. Emerg. Infect. Dis. 14, 202â209 (2008).
Norton, R. et al. Invasive group A streptococcal disease in North Queensland (1996â2001). Indian J. Med. Res. 119 (Suppl), 148â151 (2004).
Le Hello, S. et al. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever. J. Clin. Microbiol. 48, 526â530 (2010).
Steer, A. C. et al. Prospective surveillance of invasive group A streptococcal disease, Fiji, 2005â2007. Emerg. Infect. Dis. 15, 216â222 (2009).
Sriskandan, S. & Altmann, D. M. The immunology of sepsis. J. Pathol. 214, 211â223 (2008).
Stevens, D. L. Invasive group A Streptococcus infections. Clin. Infect. Dis. 14, 2â11 (1992).
van der Helm-van Mil, A. H. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Curr. Opin. Rheumatol. 22, 437â442 (2010).
van Dillen, J., Zwart, J., Schutte, J. & van Roosmalen, J. Maternal sepsis: epidemiology, etiology and outcome. Curr. Opin. Infect. Dis. 23, 249â254 (2010).
Acknowledgements
The authors thank the Australian National Health and Medicine Research Council and the US National Institutes of Health for their funding support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1
Switching mutations observed in covRS in GAS from human isolates and murine models of invasive infections (PDF 399 kb)
Related links
Glossary
- Rheumatic fever
-
An inflammatory disease caused by cross-reactive antibodies that are induced after a streptococcal infection.
- Acute glomerulonephritis
-
Inflammation of the glomeruli of the kidney that follows streptococcal infection and is caused by a build-up of immune complexes.
- Necrotizing fasciitis
-
Commonly known as flesh-eating disease; an infection of the skin, causing destruction of underlying tissues and muscle.
- Cathelicidin
-
A mammalian cationic antimicrobial polypeptide with an important role in host innate immunity and prevention of bacterial infections.
- Membrane attack complex
-
An assemblage of complement proteins that forms pores across cell membranes, resulting in cell death.
- α-defensins
-
A family of mammalian cationic antimicrobial peptides that are secreted by leukocytes and inhibit the activity of serine proteases.
- Lysozyme
-
A mammalian muramidase that catalyses the hydrolysis of bacterial cell walls.
- Subcutaneous-chamber infection model
-
A disease model system that uses micropore teflon diffusion chambers which are subcutaneously implanted into mice to enable the post-infection recovery of bacteria and immune infiltrate.
Rights and permissions
About this article
Cite this article
Cole, J., Barnett, T., Nizet, V. et al. Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol 9, 724â736 (2011). https://doi.org/10.1038/nrmicro2648
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrmicro2648
This article is cited by
-
Human CEACAM1 is targeted by a Streptococcus pyogenes adhesin implicated in puerperal sepsis pathogenesis
Nature Communications (2023)
-
Pathogen-driven degradation of endogenous and therapeutic antibodies during streptococcal infections
Nature Communications (2023)
-
A new perspective in pyroptosis: lifting the veil on GSDMA activation
Frontiers of Medicine (2023)
-
17β-Estradiol Mediates Staphylococcus aureus Adhesion in Vaginal Epithelial Cells via Estrogen Receptor α-Associated Signaling Pathway
Current Microbiology (2023)
-
Detection of Streptococcus pyogenes M1UK in Australia and characterization of the mutation driving enhanced expression of superantigen SpeA
Nature Communications (2023)